Table of Contents

1 Study Coverage

• 1.1 Female Contraception Drug Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Female Contraception Drug Market Size Growth Rate by Product
  • 1.4.2 AG-890
  • 1.4.3 Amphora
  • 1.4.4 BAY-1007626
  • 1.4.5 Drospirenone
  • 1.4.6 Others
• 1.5 Market by End User
  • 1.5.1 Global Female Contraception Drug Market Size Growth Rate by End User
  • 1.5.2 Clinic
  • 1.5.3 Hospital
  • 1.5.4 Homecare
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Female Contraception Drug Market Size
  • 2.1.1 Global Female Contraception Drug Revenue 2014-2025
  • 2.1.2 Global Female Contraception Drug Sales 2014-2025
• 2.2 Female Contraception Drug Growth Rate by Regions
  • 2.2.1 Global Female Contraception Drug Sales by Regions
  • 2.2.2 Global Female Contraception Drug Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Female Contraception Drug Sales by Manufacturers
  • 3.1.1 Female Contraception Drug Sales by Manufacturers
  • 3.1.2 Female Contraception Drug Sales Market Share by Manufacturers
  • 3.1.3 Global Female Contraception Drug Market Concentration Ratio (CR5 and HHI)
• 3.2 Female Contraception Drug Revenue by Manufacturers
  • 3.2.1 Female Contraception Drug Revenue by Manufacturers (2014-2019)
  • 3.2.2 Female Contraception Drug Revenue Share by Manufacturers (2014-2019)
• 3.3 Female Contraception Drug Price by Manufacturers
• 3.4 Female Contraception Drug Manufacturing Base Distribution, Product Types
  • 3.4.1 Female Contraception Drug Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Female Contraception Drug Product Type
  • 3.4.3 Date of International Manufacturers Enter into Female Contraception Drug Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Female Contraception Drug Sales by Product
• 4.2 Global Female Contraception Drug Revenue by Product
• 4.3 Female Contraception Drug Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Female Contraception Drug Breakdown Data by End User

6 North America

• 6.1 North America Female Contraception Drug by Countries
  • 6.1.1 North America Female Contraception Drug Sales by Countries
  • 6.1.2 North America Female Contraception Drug Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Female Contraception Drug by Product
• 6.3 North America Female Contraception Drug by End User

7 Europe

• 7.1 Europe Female Contraception Drug by Countries
  • 7.1.1 Europe Female Contraception Drug Sales by Countries
  • 7.1.2 Europe Female Contraception Drug Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Female Contraception Drug by Product
• 7.3 Europe Female Contraception Drug by End User

8 Asia Pacific

• 8.1 Asia Pacific Female Contraception Drug by Countries
  • 8.1.1 Asia Pacific Female Contraception Drug Sales by Countries
  • 8.1.2 Asia Pacific Female Contraception Drug Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Female Contraception Drug by Product
• 8.3 Asia Pacific Female Contraception Drug by End User

9 Central & South America

• 9.1 Central & South America Female Contraception Drug by Countries
  • 9.1.1 Central & South America Female Contraception Drug Sales by Countries
  • 9.1.2 Central & South America Female Contraception Drug Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Female Contraception Drug by Product
• 9.3 Central & South America Female Contraception Drug by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Female Contraception Drug by Countries
  • 10.1.1 Middle East and Africa Female Contraception Drug Sales by Countries
  • 10.1.2 Middle East and Africa Female Contraception Drug Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Female Contraception Drug by Product
• 10.3 Middle East and Africa Female Contraception Drug by End User

11 Company Profiles

• 11.1 Addex Therapeutics Ltd
  • 11.1.1 Addex Therapeutics Ltd Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Addex Therapeutics Ltd Female Contraception Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Addex Therapeutics Ltd Female Contraception Drug Products Offered
  • 11.1.5 Addex Therapeutics Ltd Recent Development
• 11.2 Agile Therapeutics Inc
  • 11.2.1 Agile Therapeutics Inc Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Agile Therapeutics Inc Female Contraception Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Agile Therapeutics Inc Female Contraception Drug Products Offered
  • 11.2.5 Agile Therapeutics Inc Recent Development
• 11.3 Bayer AG
  • 11.3.1 Bayer AG Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Bayer AG Female Contraception Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Bayer AG Female Contraception Drug Products Offered
  • 11.3.5 Bayer AG Recent Development
• 11.4 Evofem Inc
  • 11.4.1 Evofem Inc Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Evofem Inc Female Contraception Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Evofem Inc Female Contraception Drug Products Offered
  • 11.4.5 Evofem Inc Recent Development
• 11.5 Hervana Ltd
  • 11.5.1 Hervana Ltd Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Hervana Ltd Female Contraception Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Hervana Ltd Female Contraception Drug Products Offered
  • 11.5.5 Hervana Ltd Recent Development
• 11.6 Mithra Pharmaceuticals SA
  • 11.6.1 Mithra Pharmaceuticals SA Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Mithra Pharmaceuticals SA Female Contraception Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Mithra Pharmaceuticals SA Female Contraception Drug Products Offered
  • 11.6.5 Mithra Pharmaceuticals SA Recent Development
• 11.7 Orbis Biosciences Inc
  • 11.7.1 Orbis Biosciences Inc Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Orbis Biosciences Inc Female Contraception Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Orbis Biosciences Inc Female Contraception Drug Products Offered
  • 11.7.5 Orbis Biosciences Inc Recent Development
• 11.8 Teva Pharmaceutical Industries Ltd
  • 11.8.1 Teva Pharmaceutical Industries Ltd Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Teva Pharmaceutical Industries Ltd Female Contraception Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Teva Pharmaceutical Industries Ltd Female Contraception Drug Products Offered
  • 11.8.5 Teva Pharmaceutical Industries Ltd Recent Development
• 11.9 Viramal Ltd
  • 11.9.1 Viramal Ltd Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Viramal Ltd Female Contraception Drug Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Viramal Ltd Female Contraception Drug Products Offered
  • 11.9.5 Viramal Ltd Recent Development

12 Future Forecast

• 12.1 Female Contraception Drug Market Forecast by Regions
  • 12.1.1 Global Female Contraception Drug Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Female Contraception Drug Revenue Forecast by Regions 2019-2025
• 12.2 Female Contraception Drug Market Forecast by Product
  • 12.2.1 Global Female Contraception Drug Sales Forecast by Product 2019-2025
  • 12.2.2 Global Female Contraception Drug Revenue Forecast by Product 2019-2025
• 12.3 Female Contraception Drug Market Forecast by End User
• 12.4 North America Female Contraception Drug Forecast
• 12.5 Europe Female Contraception Drug Forecast
• 12.6 Asia Pacific Female Contraception Drug Forecast
• 12.7 Central & South America Female Contraception Drug Forecast
• 12.8 Middle East and Africa Female Contraception Drug Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Female Contraception Drug Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

The global Female Contraception Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Female Contraception Drug market based on company, product type, end user and key regions.

This report studies the global market size of Female Contraception Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Female Contraception Drug in these regions.
This research report categorizes the global Female Contraception Drug market by top players/brands, region, type and end user. This report also studies the global Female Contraception Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Addex Therapeutics Ltd
Agile Therapeutics Inc
Bayer AG
Evofem Inc
Hervana Ltd
Mithra Pharmaceuticals SA
Orbis Biosciences Inc
Teva Pharmaceutical Industries Ltd
Viramal Ltd

Market size by Product
AG-890
Amphora
BAY-1007626
Drospirenone
Others
Market size by End User
Clinic
Hospital
Homecare

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Female Contraception Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Female Contraception Drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Female Contraception Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Female Contraception Drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Female Contraception Drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Female Contraception Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.